Johnson & Johnson Innovation has led a $25 million Series A in targeted cancer radiotherapeutic startup Fusion Pharmaceuticals.

Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug.

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been…

Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, triggering a 30% stock drop.

Celiacs could be freed from the gluten-free aisle of the supermarket if a therapeutic approach developed by ImmusanT proves effective in trials.

Argos' cancer vaccine candidate failed a phase 3 futility analysis, wiping 65% off its stock.

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Topspin Biotech Fund (…

Apitope has posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year.

VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients.

R&D